Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656535 | 0.72 | KMT2A (0.44) | ALDH1A1KDM4ESMN1; SMN2MAPTMAPK1 | |
| SCHEMBL1368505 | 0.71 | EGLN2 (0.46) | ALDH1A1KDM4ESMN1; SMN2MAPTGAA | |
| SCHEMBL29792823 | 0.69 | DYRK1A (0.39) | DYRK1ARECQL | |
| SCHEMBL22283892 | 0.69 | DYRK1A (0.39) | DYRK1ARECQL | |
| SCHEMBL9598391 | 0.69 | KDM4E (0.44) | ALDH1A1KDM4ESMN1; SMN2MAPTMAPK1 | |
| SCHEMBL1647688 | 0.67 | SMN1; SMN2 (0.37) | ALDH1A1KDM4ESMN1; SMN2MAPTMAPK1 | |
| SCHEMBL9377657 | 0.66 | CSNK1A1 (0.43) | ALDH1A1KDM4ESMN1; SMN2MAPTMAPK1 | |
| SCHEMBL6068564 | 0.65 | ADORA3 (0.33) | KDM4ESMN1; SMN2MAPK1L3MBTL1POLB | |
| SCHEMBL5909487 | 0.65 | BACE1 (0.40) | ALDH1A1KDM4EMAPTGAADYRK1A | |
| SCHEMBL31605956 | 0.65 | BACE1 (0.40) | ALDH1A1KDM4EMAPTGAADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0745154-B1 | MULTICOMPONENT SYSTEM FOR MODIFYING, DECOMPOSING OR BLEACHING LIGNIN, LIGNIN-CONTAINING MATERIALS OR SIMILAR SUBSTANCES AND METHOD OF USING THIS SYSTEM | LIGNOZYM GMBH (DE) | 1998-09-16 | — | — | EP | claimed |
| EP-0845026-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL, Hans-Peter Dr. (DE) | 1998-06-03 | — | — | EP | claimed |
| WO-1997048786-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL HANS PETER (DE) | 1997-12-24 | — | — | WO | claimed |
| US-20060040934-A1 | Use of STAT-6 inhibitors as therapeutic agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-02-23 | — | — | US | disclosed |
| US-20030232794-A1 | Use of STAT-6 inhibitors as therapeutic agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-18 | — | — | US | disclosed |
| US-20030143199-A1 | Use of STAT-6 inhibitors as therapeutic agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| WO-2002014321-A9 | USE OF STAT-6 INHIBITORS AS THERAPEUTIC AGENTS | UNIV CALIFORNIA (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002014321-A1 | USE OF STAT-6 INHIBITORS AS THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-0845026-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL, Hans-Peter Dr. (DE) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997048786-A1 | MULTICOMPONENT SYSTEM FOR USE WITH DETERGENT SUBSTANCES | CALL HANS PETER (DE) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143199-A1 | Use of STAT-6 inhibitors as therapeutic agents | STAT4, STAT3, STAT1 | ALDH1A1 3408/4885KDM4E 1176/4885SMN1; SMN2 4147/4885 |
| US-20060040934-A1 | Use of STAT-6 inhibitors as therapeutic agents | STAT3, STAT1, STAT4 | ALDH1A1 2840/4885KDM4E 1560/4885SMN1; SMN2 4797/4885 |
| US-20030232794-A1 | Use of STAT-6 inhibitors as therapeutic agents | STAT3, STAT1, STAT4 | ALDH1A1 2840/4885KDM4E 1560/4885SMN1; SMN2 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.